🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to researchers.

A Global Challenge

Gonorrhoea infections are escalating around the world, with data suggesting more than 82 million infections per year. Notably increased rates are seen in the African continent and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an important and timely development in the reality of rising global incidence, the spread of superbugs and the very limited available drugs currently available.”

Public health authorities are particularly alarmed about the surge in antibiotic-resistant strains. The World Health Organization has designated it as a "priority pathogen". A tracking program showed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Treatment Options Gain Clearance

One new antibiotic, marketed under the name Nuzolvence, was authorized by the American regulatory agency in December for treating gonorrhoea. This infection can lead to major issues, including infertility. Scientists anticipate that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This medication, which is employed against urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This approval marks a huge turning point in the management of multidrug-resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Testing Outcomes and Global Access

According to findings detailed in a prominent scientific publication, the new drug eradicated the vast majority of cases of the STI. This puts it on an equal footing with the current standard treatment, which uses two antibiotics. The research included over 900 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the rights to license and sell the drug in many low-income and middle-income countries.

Medical professionals directly involved have expressed positive views. The availability of a single-dose, oral treatment of this kind is hailed as a "critical tool" for gonorrhoea control. This is deemed vital to alleviate the strain of the disease for individuals and to halt the transmission of highly drug-resistant gonorrhoea worldwide.